The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a huge mover today! About 698,685 shares traded hands. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 13.00% since April 4, 2016 and is uptrending. It has outperformed by 11.91% the S&P500.
The move comes after 5 months positive chart setup for the $1.98B company. It was reported on Nov, 4 by Barchart.com. We have $20.88 PT which if reached, will make NASDAQ:IRWD worth $1.05B more.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage
Out of 10 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 40% are positive. Ironwood Pharmaceuticals has been the topic of 19 analyst reports since August 6, 2015 according to StockzIntelligence Inc. WallachBeth Capital maintained the shares of IRWD in a report on Tuesday, September 27 with “Hold” rating. On Friday, November 4 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Mizuho on Monday, October 10 with “Buy”. The firm has “Buy” rating by Mizuho given on Tuesday, May 10. Goldman Sachs initiated Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, March 21. Goldman Sachs has “Neutral” rating and $14 price target. Barclays Capital maintained the shares of IRWD in a report on Friday, February 19 with “Equal-Weight” rating. Wedbush maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, October 24. Wedbush has “Neutral” rating and $13 price target. The firm has “Hold” rating by Zacks given on Monday, August 10. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Outperform” rating given on Wednesday, April 6 by Cowen & Co. Wedbush maintained the stock with “Neutral” rating in Friday, February 19 report.
According to Zacks Investment Research, “Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company’s first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.6 in Q2 2016. Its up 0.36, from 1.24 in 2016Q1. The ratio improved, as 13 funds sold all Ironwood Pharmaceuticals, Inc. shares owned while 34 reduced positions. 22 funds bought stakes while 53 increased positions. They now own 136.24 million shares or 2.82% less from 140.19 million shares in 2016Q1.
Engineers Gate Manager L P reported 82,314 shares or 0.08% of all its holdings. Mirae Asset Ltd accumulated 0.02% or 55,259 shares. Moreover, Carlson L P has 0.18% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 1.10 million shares. Royal Savings Bank Of Canada owns 1,650 shares or 0% of their US portfolio. Tower Rech Capital Lc (Trc) last reported 3,682 shares in the company. Rockefeller has 2,678 shares for 0% of their US portfolio. Platinum Mngmt has invested 0.06% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Lpl Fincl Ltd Liability Company has invested 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Blackrock Inc holds 0% or 14,309 shares in its portfolio. Citigroup, a New York-based fund reported 44,473 shares. Proshare Ltd Liability Corporation has 111,464 shares for 0.02% of their US portfolio. Morgan Stanley, a New York-based fund reported 171,596 shares. Geode Capital Management Lc has 954,033 shares for 0.01% of their US portfolio. Spark Ltd Liability Company has invested 0.42% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Airain Ltd has invested 0.04% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).
Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 4 sales for $322,283 net activity. Consylman Gina sold $2,803 worth of stock or 207 shares. OLANOFF LAWRENCE S sold $28,424 worth of stock or 2,200 shares. Gilbert Halley E also sold $247,152 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares.
Another recent and important Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news was published by Businesswire.com which published an article titled: “Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update” on November 03, 2016.
IRWD Company Profile
Ironwood Pharmaceuticals, Inc., incorporated on January 5, 1998, is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Firm operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. The Company’s product, linaclotide, which is available in the United States under the brand name LINZESS, and is available in European countries under the brand name CONSTELLA. The Firm in collaboration with Astellas Pharma Inc. (Astellas) is engaged in advancing linaclotide colonic release, a second-generation product candidate with the potential to improve abdominal pain relief in adult IBS-C patients, as well as in patients with additional GI, disorders where lower abdominal pain is a predominant symptom, such as IBS-mixed (IBS-M), ulcerative colitis and diverticulitis. In addition, the Company is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.